Association between use of ticagrelor as compared with clopidogrel and bleeding outcomes stratified by estimated glomerular filtration rate (eGFR)
| eGFR (mL/min/1.73 m2) | Events (n) and event rate (%/year) | Crude analysis (95% CI) | Adjusted analysis (95% CI) | P for interaction | |||||||||
| >60 | 30–60 | <30 | >60 | 30–60 | <30 | >60 | 30–60 | <30 | |||||
| Ticagrelor, N=9538 | Clopidogrel, N=24 130 | Ticagrelor, N=1986 | Clopidogrel, N=7817 | Ticagrelor, N=210 | Clopidogrel, N=1525 | N=33 668 | N=9803 | N=1735 | N=33 668 | N=9803 | N=1735 | ||
| Risk of bleeding | |||||||||||||
| Readmission with bleeding | 241 (3.7) | 732 (3.2) | 94 (7.4) | 397 (5.6) | 20 (15.0) | 121 (9.1) | 1.05 (0.90 to 1.22)* | 1.17 (0.93 to 1.48)* | 1.48 (0.91 to 2.40)* | 1.10 (0.90 to 1.35)* | 1.13 (0.84 to 1.51)* | 1.79 (1.00 to 3.21)* | 0.3 |
| In-hospital bleeding in PCI-treated patients | 268 (2.9) | 456 (2.3) | 121 (5.4) | 199 (4.2) | 16 (6.0) | 34 (4.7) | 1.27 (1.09 to 1.48)† | 1.42 (1.12 to 1.79)† | 1.29 (0.68 to 2.33)† | 1.41 (1.13 to 1.78)† | 1.53 (1.11 to 2.11)† | 1.35 (0.58 to 3.25)† | n/a |
*HR
†OR.
n/a, not available; PCI, percutaneous coronary intervention.